Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
STAR Protocols
|
September 2, 2022
Mass cytometry immunostaining protocol for multiplexing clinical samples
Ramy Gadalla, Giselle M Boukhaled, David G Brooks, et al.
Plos One
|
May 31, 2019
The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients
Moshira Ezzat Saleh, Ramy Gadalla, Hebatallah Hassan, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis
Ramy Gadalla, Hebatallah Hassan, Sherif Abdelaziz Ibrahim, et al.
Journal of Advanced Research
|
March 23, 2019
Inflammatory breast cancer: Activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a/b-β-catenin signalling, the stem cell phenotype and disease progression
Hossam T Mohamed, Ramy Gadalla, Noura El-Husseiny, et al.
Pain Physician
|
August 7, 2025
Extended Relief at All Spinal Regions and Lower Lumbar VAS: Endoscopic Rhizotomy vs. Radiofrequency Ablation: A Retrospective Cohort Study
Ramy Gadalla, Mani Nathan Nair, Christopher Spevak, et al.
Molecular Cancer
|
March 9, 2017
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Sherif Abdelaziz Ibrahim, Ramy Gadalla, Eslam A El-Ghonaimy, et al.
Frontiers in Oncology
|
June 6, 2019
Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials
Ramy Gadalla, Babak Noamani, Bethany L MacLeod, et al.
Nature Communications
|
February 6, 2024
Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient
Scott C Lien, Dalam Ly, S Y Cindy Yang, et al.
Immunity
|
November 12, 2022
The transcription factor IRF2 drives interferon-mediated CD8<sup>+</sup> T cell exhaustion to restrict anti-tumor immunity
Sabelo Lukhele, Diala Abd Rabbo, Mengdi Guo, et al.
Nature Immunology
|
July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy
Giselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
STAR Protocols
|
September 2, 2022
Mass cytometry immunostaining protocol for multiplexing clinical samples
Ramy Gadalla, Giselle M Boukhaled, David G Brooks, et al.
Plos One
|
May 31, 2019
The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients
Moshira Ezzat Saleh, Ramy Gadalla, Hebatallah Hassan, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis
Ramy Gadalla, Hebatallah Hassan, Sherif Abdelaziz Ibrahim, et al.
Journal of Advanced Research
|
March 23, 2019
Inflammatory breast cancer: Activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a/b-β-catenin signalling, the stem cell phenotype and disease progression
Hossam T Mohamed, Ramy Gadalla, Noura El-Husseiny, et al.
Pain Physician
|
August 7, 2025
Extended Relief at All Spinal Regions and Lower Lumbar VAS: Endoscopic Rhizotomy vs. Radiofrequency Ablation: A Retrospective Cohort Study
Ramy Gadalla, Mani Nathan Nair, Christopher Spevak, et al.
Molecular Cancer
|
March 9, 2017
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Sherif Abdelaziz Ibrahim, Ramy Gadalla, Eslam A El-Ghonaimy, et al.
Frontiers in Oncology
|
June 6, 2019
Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials
Ramy Gadalla, Babak Noamani, Bethany L MacLeod, et al.
Nature Communications
|
February 6, 2024
Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient
Scott C Lien, Dalam Ly, S Y Cindy Yang, et al.
Immunity
|
November 12, 2022
The transcription factor IRF2 drives interferon-mediated CD8<sup>+</sup> T cell exhaustion to restrict anti-tumor immunity
Sabelo Lukhele, Diala Abd Rabbo, Mengdi Guo, et al.
Nature Immunology
|
July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy
Giselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Page
of 2